Multi-year Revenue GrowthSustained top-line expansion more than doubled revenue over four years, indicating durable demand for tertiary/quaternary hospital services. This broad revenue base supports reinvestment capacity, scale benefits in procurement and clinician attraction, and underpins medium-term growth prospects.

Improving Profitability MarginsRising gross and net margins demonstrate improving operational efficiency and pricing mix, reducing sensitivity to volume swings. Higher margins enhance cash generation potential and resilience to input-cost inflation, supporting sustainable earnings and internal funding for strategic investments.

Low Leverage, Strong Equity PositionA conservative capital structure with low leverage and a strong equity base preserves financial flexibility for capacity expansion or capex. Low debt reduces interest burden and refinancing risk, enabling management to pursue strategic initiatives without jeopardizing solvency over the medium term.

Bears Say

Decline In Cash BalancesLower cash reserves reduce the company's buffer against cyclical patient volumes or unexpected capex, increasing reliance on operating cash flow and short-term financing. Over 2–6 months this could constrain discretionary spending or delay strategic investments if cash generation weakens further.

Weaker 2025 Operating/free Cash FlowA drop in operating and free cash flow, despite healthy accounting profits, signals potential timing or working-capital pressures. Persisting cash-flow softness can limit dividend capacity, capex funding, and bulk-negotiation leverage, reducing financial resilience over the medium term.

Geographic/partner ConcentrationConcentration in a single major hospital and reliance on an Apollo brand association concentrates operational and reputational risk. Undefined contractual terms with the brand/partner may expose margins or referral flows to renegotiation or operational constraints, limiting diversification.

INDRAMEDCO FAQ

What was Indraprastha Medical Corporation Limited’s price range in the past 12 months?

Indraprastha Medical Corporation Limited lowest stock price was ₹307.90 and its highest was ₹640.05 in the past 12 months.

What is Indraprastha Medical Corporation Limited’s market cap?

Indraprastha Medical Corporation Limited’s market cap is ₹38.76B.

When is Indraprastha Medical Corporation Limited’s upcoming earnings report date?

Indraprastha Medical Corporation Limited’s upcoming earnings report date is May 15, 2026 which is in 81 days.

How were Indraprastha Medical Corporation Limited’s earnings last quarter?

Indraprastha Medical Corporation Limited released its earnings results on Feb 03, 2026. The company reported ₹4.8 earnings per share for the quarter, beating the consensus estimate of N/A by ₹4.8.

Is Indraprastha Medical Corporation Limited overvalued?

According to Wall Street analysts Indraprastha Medical Corporation Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Indraprastha Medical Corporation Limited pay dividends?

Indraprastha Medical Corporation Limited pays a Annually dividend of ₹4.5 which represents an annual dividend yield of 0.96%. See more information on Indraprastha Medical Corporation Limited dividends here

What is Indraprastha Medical Corporation Limited’s EPS estimate?

Indraprastha Medical Corporation Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Indraprastha Medical Corporation Limited have?

Indraprastha Medical Corporation Limited has 91,673,000 shares outstanding.

What happened to Indraprastha Medical Corporation Limited’s price movement after its last earnings report?

Indraprastha Medical Corporation Limited reported an EPS of ₹4.8 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 5.119%.

Which hedge fund is a major shareholder of Indraprastha Medical Corporation Limited?

Currently, no hedge funds are holding shares in IN:INDRAMEDCO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Indraprastha Medical Corporation Limited

Indraprastha Medical Corporation Limited provides hospital services in India. It offers services primarily in the areas of anesthesiology, pediatric, elder care, genomic medicine, health check, sugar, bariatric and metabolic surgery, bone marrow transplant, cancer, cardiac and cardiology, dermatology, dietetics and clinical nutrition, emergency care, endovascular surgery, endocrinology/diabetes care, ENT, fetal medicine, gastroenterology and hepatology, laparoscopic surgery, gynecology and obstetrics, hyperbaric oxygen therapy, IVF, internal medicine, laboratory services, neonatology, nephrology, neurosciences, nuclear medicine, ophthalmology, orthopedic, pediatric urology and pediatric surgery, physiotherapy and rehabilitation, psychiatry and clinical psychology, radiology/radio diagnosis, respiratory sleep medicine and critical care, rheumatology, robotic surgery, spine surgery, transfusion medicine, transplant, and urology and andrology. The company operates cosmetic and dental clinics. Indraprastha Medical Corporation Limited was incorporated in 1988 and is based in New Delhi, India.